Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers

Hillstream BioPharma, Inc. announced the signing of an exclusive agreement with Applied Biomedical Science Institute to license technology for human antibodies targeting novel HER2 and HER3 Conformational Epitope. The HER2/HER3 binding antibody drug conjugate is targeted to have a high drug-to-antibody ratio which should increase the anti-tumoral efficacy with an enhanced bystander killing effect.